Recent Quotes (30 days)

You have no recent quotes
chg | %

Medmira Inc  

(Public, CVE:MIR)   Watch this stock  
Find more results for MIR
0.0000 (0.00%)
Delayed:   10:52AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.02 - 0.05
Open     -
Vol / Avg. 0.00/35,883.00
Mkt cap 16.46M
P/E     -
Div/yield     -
EPS -0.01
Shares 658.36M
Beta -0.47
Inst. own     -
Nov 27, 2017
Q4 2017 MedMira Inc Earnings Release (Estimated) Add to calendar

Key stats and ratios

Q2 (Apr '17) 2016
Net profit margin -390.35% -228.57%
Operating margin -324.64% -198.46%
EBITD margin - -194.04%
Return on average assets -398.10% -388.79%
Return on average equity - -
Employees 65 -
CDP Score - -


Suite 1, 155 Chain Lake Dr
+1-902-4501588 (Phone)
+1-902-4501580 (Fax)

Website links


MedMira Inc. is a biotechnology company. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company operates through the rapid diagnostic products and services segment. The Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its research focuses on specific areas of the diagnostics market, such as rapid, point-of-care and in vitro sectors. The RVF technology platform includes a three component system: a test cartridge, multi-function buffer and InstantGold Cap. Its technology can be applied in healthcare, research and industrial markets. It offers rapid tests for testing serum, plasma or whole blood specimens. The Company's tests are sold under brands, including Reveal, Multiplo and Miriad. The Company offers rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis.

Officers and directors

Marvyn Robar Independent Chairman of the Board
Hermes Chan Chief Executive Officer, Director
Markus M. Meile Chief Financial Officer
Sing Chan Chief Operating Officer
Robyn Cook Chief Corporate Officer, Corporate Secretary
Shou-Ching Tang M.D. Director